Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Postprandial metabolomics analysis reveals disordered serotonin metabolism in post-bariatric hypoglycemia
Rafael Ferraz-Bannitz, … , Darleen A. Sandoval, Mary-Elizabeth Patti
Rafael Ferraz-Bannitz, … , Darleen A. Sandoval, Mary-Elizabeth Patti
Published September 12, 2024
Citation Information: J Clin Invest. 2024;134(21):e180157. https://doi.org/10.1172/JCI180157.
View: Text | PDF
Clinical Research and Public Health Endocrinology Metabolism

Postprandial metabolomics analysis reveals disordered serotonin metabolism in post-bariatric hypoglycemia

  • Text
  • PDF
Abstract

BACKGROUND Bariatric surgery is a potent therapeutic approach for obesity and type 2 diabetes but can be complicated by post-bariatric hypoglycemia (PBH). PBH typically occurs 1–3 hours after meals, in association with exaggerated postprandial levels of incretins and insulin.METHODS To identify mediators of disordered metabolism in PBH, we analyzed the plasma metabolome in the fasting state and 30 and 120 minutes after mixed meal in 3 groups: PBH (n = 13), asymptomatic post–Roux-en-Y gastric bypass (post-RYGB) (n = 10), and nonsurgical controls (n = 8).RESULTS In the fasting state, multiple tricarboxylic acid cycle intermediates and the ketone β-hydroxybutyrate were increased by 30%–80% in PBH versus asymptomatic. Conversely, multiple amino acids (branched-chain amino acids, tryptophan) and polyunsaturated lipids were reduced by 20%–50% in PBH versus asymptomatic. Tryptophan-related metabolites, including kynurenate, xanthurenate, and serotonin, were reduced 2- to 10-fold in PBH in the fasting state. Postprandially, plasma serotonin was uniquely increased 1.9-fold in PBH versus asymptomatic post-RYGB. In mice, serotonin administration lowered glucose and increased plasma insulin and GLP-1. Moreover, serotonin-induced hypoglycemia in mice was blocked by the nonspecific serotonin receptor antagonist cyproheptadine and the specific serotonin receptor 2 antagonist ketanserin.CONCLUSION Together these data suggest that increased postprandial serotonin may contribute to the pathophysiology of PBH and provide a potential therapeutic target.FUNDING National Institutes of Health (NIH) grant R01-DK121995, NIH grant P30-DK036836 (Diabetes Research Center grant, Joslin Diabetes Center), and Fundação de Amparo à Pesquisa do Estado de São Paulo grant 2018/22111-2.

Authors

Rafael Ferraz-Bannitz, Berkcan Ozturk, Cameron Cummings, Vissarion Efthymiou, Pilar Casanova Querol, Lindsay Poulos, Hanna Wang, Valerie Navarrete, Hamayle Saeed, Christopher M. Mulla, Hui Pan, Jonathan M. Dreyfuss, Donald C. Simonson, Darleen A. Sandoval, Mary-Elizabeth Patti

×

Figure 6

Serotonin induces hypoglycemia during meal tolerance test; hypoglycemia is blocked by cyprophetadine and more specifically by ketanserin.

Options: View larger image (or click on image) Download as PowerPoint
Serotonin induces hypoglycemia during meal tolerance test; hypoglycemia ...
Reductions in glucose are blocked by the serotonin antagonist cyproheptadine and the specific serotonin receptor 2 antagonist ketanserin. (A) Scheme showing administration of cyproheptadine (50 mg/kg) or saline and, after 30 minutes, oral gavage with 200 μL of Ensure, insulin injection (2 U/kg), and administration of serotonin (20 mg/kg) or saline in C57BL/6J mice. MMTT, mixed meal tolerance test. (B) Glucose levels during experiment. (C) Scheme showing administration of ketanserin (5 mg/kg) and exogenous administration of serotonin (20 mg/kg) or saline in C57BL/6J mice. (D) Glucose levels after serotonin or saline injection. (E and F) Insulin levels (E) and GLP-1 levels (F) after serotonin or saline injection. In all panels, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by 2-way ANOVA with Tukey’s multiple-comparison test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts